BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is a very potent inhibitor of tyrosine kinases such as ABL kinase, chimeric oncoprotein BCR-ABL of chronic myeloid leukemia, transmembrane KIT receptors, PDGFRα, and PDGFRb.